GAD

Foster Counseling and Therapy Announces Specialized Anxiety and OCD Services in Lake in the Hills

Retrieved on: 
Dienstag, Mai 7, 2024
ACT, Grief, LCPC, Social anxiety, OCD, Acceptance, Phobia, ERP, Psychotherapy, Exposure, ADHD, Obsessive–compulsive disorder, GAD, Response, Anxiety, Mental health, Panic, Attention deficit hyperactivity disorder, Judgement, Commitment, Community, Individual, Outline of counseling, Nursing

Foster Counseling and Therapy is proud to announce its specialized services for anxiety and Obsessive-Compulsive Disorder (OCD) in the Lake in the Hills community.

Key Points: 
  • Foster Counseling and Therapy is proud to announce its specialized services for anxiety and Obsessive-Compulsive Disorder (OCD) in the Lake in the Hills community.
  • Recognized for an inclusive and comprehensive approach, the clinic features a team of highly educated and extensively trained specialists in OCD and Anxiety Therapy .
  • The clinic’s tailored services cater to a broad spectrum of anxiety disorders, including generalized anxiety disorder (GAD), social anxiety, panic disorders, phobias, and OCD.
  • Community members seeking help are encouraged to contact Foster Counseling and Therapy to discover how these specialized services can significantly improve their mental health and well-being.

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

Retrieved on: 
Donnerstag, Mai 9, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, IDR, HCP, MindMed, Abbreviation, USPSTF, Wellness, National Health, Presenteeism, GAD, HC, Patient, Absenteeism, Multimedia, Anxiety, Nursing

Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay.

Key Points: 
  • Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay.
  • (Graphic: Business Wire)
    Three studies examined the impact of GAD on healthcare utilization and costs, workplace productivity, and healthcare quality of life (HC QOL).
  • “These studies clearly demonstrate that the burden of GAD on the US healthcare system, employers, and people living with GAD is enormous.
  • “We undertook these studies as part of our commitment to highlight the scale of the anxiety crisis and our mission to address this burden.

MindMed Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
Mittwoch, Mai 8, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, FDA, MindMed, ASD, Medicine, GAD, Week, Spectrum, BTD, ODT, Prevalence, Pharmaceutical industry

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.
  • For the quarter ended March 31, 2024, net cash used in operating activities was $16.6 million, compared to $13.3 million in the quarter ended March 31, 2023.
  • Net loss for the quarter ended March 31, 2024 was $54.4 million, compared to $24.8 million for the quarter ended March 31, 2023.
  • MindMed management will host a conference call at 4:30 PM EDT today to provide a corporate update and review the Company’s first quarter 2024 financial results.

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones 

Retrieved on: 
Montag, Mai 6, 2024
Biotechnology, FDA, Mental Health, Health, Pharmaceutical, Clinical trial, Safety, Depression, GAD, DSM-IV codes, IM, BTD, Aes, Inc., Anxiety, Tryptamine, MDD, Prevalence, Open access, Pharmaceutical industry

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, provides a corporate update highlighting recent clinical accomplishments and key upcoming catalysts across its development pipeline.
  • Our team is dedicated to turning the tide of the mental health crisis through our clinical-stage programs,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • The BTD by the FDA validates CYB003's potential to show significant clinical improvements over existing treatments based on preliminary results and serves to expedite CYB003’s development pathway towards commercialization.
  • Cybin is also developing EMBARK for Clinical Trials (“EMBARKCT”), a scalable model of psychedelic facilitation training that will enable the Company to effectively screen, qualify, and train facilitators to participate in future pivotal trials.

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

Retrieved on: 
Samstag, Mai 4, 2024
General Health, Health, Mental Health, APA, FDA, MindMed, Medicine, GAD, Week, Pharmaceutical industry

MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints.

Key Points: 
  • MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints.
  • The study was presented at the APA Annual Meeting, the largest psychiatry-focused scientific meeting in the world, in New York City being held May 4 – 8, 2024.
  • MM120 was administered as a single dose in a monitored clinical setting, with no additional therapeutic intervention, to demonstrate the medication’s effect.
  • In today’s presentation of the Phase 2b study with MM120, investigators presented results from the assessment of several additional secondary endpoints that were pre-specified.

Incannex Healthcare Inc. Quarterly Update, Q1 2024

Retrieved on: 
Dienstag, April 16, 2024
FDA, Psilocybin, Pregabalin, Risk, Obstruction, Phase II, IND, NCT, GAD, Serotonin, Biomarker, Sleep, Deficit spending, Inflammation, Benzodiazepine, Pharmacokinetics, Food, HCQ, IRB, Psychotherapy, Diazepam, Quality of life, OSA, Food and Drug Administration, Pain, Patient, Somnolence, Institutional review board, Safety, Tissue, Bronchitis, PRO, Research, Monash University, Joint, Fatigue, EMA, Dronabinol, PAP, Clinical trial, Asthma, AHI, Accident, COPD, Acetazolamide, NDA, Rheumatoid arthritis, Colitis, Joint stiffness, Obstructive sleep apnea, CBD, Disease, Inflammatory bowel disease, Sleep apnea, Hydroxychloroquine, Cannabidiol, Pharmaceutical industry

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Clinical stage pharmaceutical development company, Incannex Healthcare Inc. (NASDAQ: IXHL), (‘Incannex’ or the ‘Company’), is pleased to provide quarterly activities update and for the quarter ended 31 March 2024.
  • Incannex is undertaking various U.S. Food and Drug Administration (‘FDA’) research and development (‘R&D’) programs for cannabinoid pharmaceutical products and psychedelic medicine therapies.
  • During the quarter, Incannex released top line results from the PsiGAD1 clinical trial conducted at Monash University, based in Melbourne, Australia.
  • This announcement has been approved for release to NASDAQ by the Incannex Board of Directors.

MindMed to Present at Upcoming May Medical Conferences

Retrieved on: 
Donnerstag, April 25, 2024
Mental Health, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, APA, Congress, American Psychiatric Association, MindMed, Epidemiology, Medicine, GAD, Pharmacoeconomics, Lysergic acid diethylamide

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
    American Psychiatric Association (APA) 2024 Congress, New York, NY
    Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
    International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta, GA
    Posters will be available on MindMed’s Company website following the conferences.

BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001

Retrieved on: 
Mittwoch, April 3, 2024
GAD, Metabolism, MDD, LSD, Patient, Research, Lysergic acid diethylamide, DSM-IV codes, IND, Hallucination, Safety, GLP, Multilateral, Medical device

The IND-enabling cardio-pulmonary GLP studies have been completed, and the metabolism and genotoxicity GLP studies are to be initiated shortly.

Key Points: 
  • The IND-enabling cardio-pulmonary GLP studies have been completed, and the metabolism and genotoxicity GLP studies are to be initiated shortly.
  • Dr. Ahmad Doroudian, CEO of BetterLife, commented, “We are very encouraged with FDA’s recent decision to grant breakthrough therapy designation to LSD for generalized anxiety disorder (GAD) patients.
  • In simple words, we believe BETR-001 will deliver all the therapeutic benefits of LSD without its side effects.”
    BetterLife issued a total of $1.168 million 10% convertible debentures (the “Convertible Debentures”).
  • $800,000 of the Convertible Debentures mature on March 27, 2026 and $368,000 mature on April 1, 2026.

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Retrieved on: 
Freitag, März 15, 2024
Research, Mental Health, FDA, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, GAD, Selective serotonin reuptake inhibitor, Breakthrough therapy, Inc., Patient, Disease, Human, Anxiety, DMT, Epidemiology, Psychiatry, Anxiety disorder, Safety, E36, Food, Pharmaceutical industry

“Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.

Key Points: 
  • “Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • The CYB004-002 Phase 2 study is a randomized, double-blind study which will evaluate the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed.
  • The study will enroll participants with moderate to severe GAD and a score of ≥10 on the GAD-7 anxiety scale.
  • Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019.

Dr. Bill Winston Welcomed Thousands of Attendees and Awarded Nearly $20,000 to Entrepreneurs at 2024 Business & Leadership Conference

Retrieved on: 
Dienstag, April 2, 2024
E-commerce, Bible, GAD, BLC, Conference, Black panther, Television, Education, Religion, Knowledge, Lead, Information technology, Palate, Entrepreneurship, AI, Poverty, Star Trek, JBS, Global Entrepreneur, TED (conference), Government, Parent

CHICAGO, April 2, 2024 /PRNewswire/ -- Dr. Bill Winston, a globally renowned pastor, entrepreneur, and business leader, presented the 2024 Business & Leadership Conference (BLC) from March 22-23, where thousands of entrepreneurs and leaders gathered in-person and online, to equip themselves with business strategies and tools to create their own economies and dominate their industries. The free, two-day hybrid conference welcomed entrepreneurs, business, and faith leaders from around the world who were empowered to take the lead in areas of influence – business, government, religion, education, media, arts, entertainment, etc. – by receiving professional insights and the tools needed to bring their businesses to fruition.

Key Points: 
  • The free, two-day hybrid conference welcomed entrepreneurs, business, and faith leaders from around the world who were empowered to take the lead in areas of influence – business, government, religion, education, media, arts, entertainment, etc.
  • BLC was hosted by the nationally accredited Joseph Business School (JBS) , which celebrated 25 years this year.
  • Founded by Dr. Bill Winston, the school, which has a campus and online program, teaches business leaders and entrepreneurs how to excel in the marketplace using the practical and spiritual principles found in the Bible.
  • For more information or to view the 2024 speaking engagements, interviews and special events, please visit https://blc.billwinston.org , the JBS YouTube page , or https://jbs.edu/ .